Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
- Drug Discovery
- ribonucleic acid
IPSCIO Report Record List
IPSCIO Record ID: 248304
Licensor hereby grants to Licensee an exclusive royalty-bearing right and license under the Patent Rights to manufacture, use, offer for sale, sell and import Licensed Products for human diagnostic uses in the Territory in the Fields solely as expressly set forth in this Agreement. From time to time during the term of this Agreement, Licensee shall have the right, on notice to Licensor, to nominate a specific Licensed Product for diagnostic uses, which Licensed Product shall. at the time of such nomination, be currently the subject of a discovery or development program of Licensee or a Sublicensee or approved for a therapeutic use in one of the Fields.
(1) one or more genomes or RNA transcripts of a virus or a pathogenic organism (Pathogen RNA), or (2) RNAs that Localize in. or traffic to, the cytoplasm (Cytoplasmic RNA). For the avoidance of doubt, a product otherwise meeting the criteria set forth that targets a Pathogen RNA and also targets Cytoplasmic RNAs shall be considered a Licensed Product. For the purposes of the definition of Licensed Product, targets means possessing a degree of Watson-Crick base pairing between the Licensed Product and either Pathogen RNA or Cytoplasmic RNA that is sufficient to promote RNA induced silencing. By way of further clarification, Licensed Product shall include a product manufactured in a country in which such manufacture is Covered by a Valid Claim and thereafter exported to and sold in a country in which no Valid Claim exists.
Patent Rights means
11/079,906 – Methods and compositions for the specific inhibition of gene expression by double stranded RNA.
11/079,476 – Methods and compositions for the specific inhibition of gene expression by double stranded RNA.
11/797,296 – Methods and compositions for the specific inhibition of gene expression by double stranded RNA.
IPSCIO Record ID: 248305
8,097,710 – Gene silencing
8,258,285 – RNA molecules and vectors for gene silencing
8,263,569 – Gene silencing
8,299,235 – RNA molecules and vectors for gene silencing
8,349,607 – Gene silencing
SRM shall mean a short RNA molecule or molecules nominated by Licensee hereof. Such SRM will be designed to target and modify the expression of a human gene or genes, where such human gene or genes may be any genes selected from across the human genome and may contain a single short RNA molecule or the combination of rwo such short RNA molecules. Such SRM may comprise an SRM series to provide for lead drug candidate and back-up drug candidate (including different formulations, siRNA sequences or siRNA modifications) addressing the same human gene target. Without limitation to the foregoing and for purposes of clarity, an SRM may comprise short RNA molecules designed to target a combination of two (but no more than two) separate gene targets in the human genome.
IPSCIO Record ID: 352695
– Allele-specific RNA Interference;
– In Vivo Production of Small Interfering RN As that Mediate Gene Silencing;
– RNA Interference for the Treatment of Gain-of-Function Disorders;
– Novel AAVs and Uses Thereof;
– CNS Targeting AAV Vectors and Methods of Use Thereof;
– Methods and Compositions for Controlling Efficacy of RNA Silencing;
– Methods and Compositions for Enhancing the Efficacy and Specificity of Single and Double Blunt-Ended siRNA; and,
– Methods and Compositions for Enhancing the Efficacy and Specificity of RNAi.
from the Field.
The gene therapy approach uses AAV (adeno-associated virus) vectors, which are modified, non-replicating versions of AAV, and which we believe are ideal vectors for CNS gene therapy.
The Licensee expects to utilize established and novel techniques for dosing and delivery of our AAV gene therapies to the CNS.
IPSCIO Record ID: 344567
For the Development License, a co-exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Develop Licensed Products in the Field for the Profit-Share Territory, and an exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Develop Licensed Products in the Field for the Royalty Territory.
For the Commercialization License, an exclusive right and license, with the right to grant sublicenses, under the Licensor Technology to Commercialize Licensed Products in the Field in the Territory.
For the Manufacturing License, a co-exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Manufacture or have Manufactured Licensed Products for Development and Commercialization in the Field for the Territory.
RNAI Modulation of RSV and Therapeutic Uses Thereof,
Inhaled Treatment for RSV,
Methods and Compositions for Prevention or Treatment of RSV Infection,
Model for RSV Infection,
Methods and Compositions for Inhibiting the Function of Polynucleotide Sequences,
Use of Double Stranded RNA For Identifying Nucleic Acid Sequences That Modulate the Function of a Cell, and, Influenza siRNA Molecules, Expression Constructs. Compositions. and Methods of Use.
Licensor owns or controls certain fundamental intellectual properties relating to RNA interference, and is developing therapeutic products targeting respiratory syncytial virus that function through RNA interference, including the proprietary Licensor product known as ALN-RSV01.
ALN-RSV01 is a synthetic double-stranded RNA (dsRNA) oligonucleotide formed by the hybridization of two partially complementary single-strand RN As in which the 3 ends of each strand are capped with two thymidine units (dT).
ALN-RSVO1 drug product is formulated as a sterile phosphate-buffered solution for dilution with normal saline prior to administration.
Licensed Products means any RNAi Product directed to RSV.
RSV means all strains of the respiratory syncytial virus.
RSVOl Product means any product containing Licensors proprietary composition known as ALN-RSVO1.
RSV02 Product means any product containing Licensors proprietary composition designated by the JSC as ALN-RSV02.
Directly Competitive Product means any therapeutic or prophylactic product that specifically targets RSV. For avoidance of doubt, Directly Competitive Product as to a Party shall not include a product with broad antiviral activity that may also target RSV as long as any Development of such product as a treatment or
prophylaxis of RSV in humans has been limited to discovery, research and preclinical Development work up to, but not including, IND-enabling studies.
Licensee will develop and commercialize such therapeutic RNA interference products for the treatment of respiratory infections in humans caused by RSV, throughout the world, excluding Japan and certain other countries in Asia.
IPSCIO Record ID: 223124
RNA interference, or RNAi, is a naturally occurring mechanism within cells for selectively silencing specific genes, an ability that could become the basis for a whole new class of therapeutic products. The discovery of RNAi has been heralded by many as a major breakthrough, and the journal Science named RNAi the top scientific achievement of 2002 as well as one of the top ten scientific advances of 2003. Because many diseases are caused by the inappropriate activity of specific genes, the ability to silence such genes selectively through RNAi could provide a means to treat a wide range of human diseases.
Licensed Patents means the U.S. Patent Applications listed below and any divisions, continuations, reissues, reexamines, extensions and continuations-in-part applications thereof and any patents issuing thereto; and any and all foreign patents, foreign applications, extensions and supplemental protection certificates or patent applications corresponding thereto having the Principal Investigator as an inventor and claiming the same priority date as a parent application.
Serial No. Type Tite Date Filed Status
PCT/US01/08435 PCT Methods and Compositions for RNA Interference 3/16/01 Published
09/858,862 CIP Methods and Compositions for RNA Interference 5/16/01 Pending
09/866,551 CIP Methods and Compositions for RNA Interference 5/24/01 Pending
10/055,797 CIP Methods and Compositions for RNA Interference 1/22/02 Pending
Licensed Product means any product, including but not limited to any lyophilized liquid, sustained release or aerosolized formulation or other formulation, or process for which Licensee, or its Affiliate has received FDA Approval and/or Regulatory Approval, which is made through the use of Licensor Know-How or falls within the scope of a Valid Claim of a Licensed Patent.
IPSCIO Record ID: 1417
(i) an exclusive, royalty-bearing license under its rights in Patent Rights to make, have made, use, have used, Sell and have Sold Products and Processes; and
(ii) the right to grant sublicenses under the rights granted (a)(i) to Sublicensees.
The Licensee was founded in May 2012 with the goal of developing a treatment for cystic fibrosis.